Patents by Inventor Chundao Yang

Chundao Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CLASS OF 1,7-NAPHTHYRIDINE COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20240043419
    Abstract: A class of 1,7-naphthyridine compounds and an application thereof, the compounds being compounds represented by formula (II) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 27, 2021
    Publication date: February 8, 2024
    Applicant: Medshine Discovery Inc.
    Inventors: Shaohui Wang, Chundao Yang, Shuhui Chen
  • 1H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20230357241
    Abstract: A series of 1H-pyrrolo[2,3-c]pyridine compounds and an application thereof are provided. The compounds include those represented by formula (P) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Inventors: Wenyuan QIAN, Xiawei WEI, Chundao YANG, Guanghai XU, Ning JIANG, Shuhui CHEN
  • Macrocyclic compound serving as Wee1 inhibitor and applications thereof
    Patent number: 11613545
    Abstract: Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: March 28, 2023
    Assignee: WUXI BIOCITY BIOPHARMACEUTICS CO., LTD.
    Inventors: Wenyuan Qian, Chundao Yang, Zhengwei Li, Jie Li, Jian Li, Shuhui Chen
  • CRYSTAL FORM OF WEE1 INHIBITOR COMPOUND AND USE THEREOF
    Publication number: 20220220120
    Abstract: Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.
    Type: Application
    Filed: April 30, 2020
    Publication date: July 14, 2022
    Inventors: Wenyuan QIAN, Chundao YANG, Zhengwei LI, Jie LI, Jian LI, Shuhui CHEN
  • Heterocyclic compound as CSF-1R inhibitor and use thereof
    Patent number: 11384065
    Abstract: The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 12, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guanghai Xu, Jie Li, Jian Li, Shuhui Chen
  • Prostacyclin receptor agonist
    Patent number: 11299475
    Abstract: A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: April 12, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guanghai Xu, Jian Li, Shuhui Chen
  • Quinolino-pyrrolidin-2-one derivative and application thereof
    Patent number: 11230549
    Abstract: Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan Qian, Chundao Yang, Guoqiang Dai, Jian Li, Shuhui Chen
  • PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
    Publication number: 20210403451
    Abstract: A pyrimidopyrazolone derivative as a Wee1 inhibitor and use thereof in preparation of a medicament for treating Wee1-related diseases are described. In particular, the present invention relates to a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 28, 2019
    Publication date: December 30, 2021
    Inventors: Wenyuan QIAN, Chundao YANG, Zhengwei LI, Jian LI, Shuhui CHEN
  • QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF
    Publication number: 20210380599
    Abstract: Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.
    Type: Application
    Filed: September 27, 2019
    Publication date: December 9, 2021
    Inventors: Wenyuan QIAN, Chundao YANG, Guoqiang DAI, Jian LI, Shuhui CHEN
  • MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST
    Publication number: 20210338665
    Abstract: The present disclosure provides application of a compound in conformity with a general formula I, and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating and/or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease or a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.
    Type: Application
    Filed: June 5, 2019
    Publication date: November 4, 2021
    Applicants: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.
    Inventors: Kunlun HE, Zeyu ZHANG, Xiaojian GAO, Chunlei LIU, Xin LI, Chen LI, Wenyuan QIAN, Chundao YANG, Guanghai XU, Yiwei WANG
  • HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF
    Publication number: 20210107894
    Abstract: The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
    Type: Application
    Filed: January 3, 2019
    Publication date: April 15, 2021
    Applicants: MEDSHINE DISCOVERY INC., MEDSHINE DISCOVERY INC.
    Inventors: Wenyuan QIAN, Chundao YANG, Guanghai XU, Jie LI, Jian LI, Shuhui CHEN
  • PROSTACYCLIN RECEPTOR AGONIST
    Publication number: 20210087168
    Abstract: A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.
    Type: Application
    Filed: February 2, 2019
    Publication date: March 25, 2021
    Inventors: Wenyuan QIAN, Chundao YANG, Guanghai XU, Jian LI, Shuhui CHEN
  • 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
    Patent number: 10954253
    Abstract: The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee1, and includes an application of the compound in treating various types of tumors.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: March 23, 2021
    Assignee: SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.
    Inventors: Wenyuan Qian, Chundao Yang, Zhengwei Li, Jie Li, Jian Li, Shuhui Chen
  • MACROCYCLIC COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATIONS THEREOF
    Publication number: 20200325145
    Abstract: Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 31, 2018
    Publication date: October 15, 2020
    Inventors: Wenyuan QIAN, Chundao YANG, Zhengwei LI, Jie LI, Jian LI, Shuhui CHEN
  • PDE4 inhibitor
    Patent number: 10662189
    Abstract: Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: May 26, 2020
    Assignee: SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.
    Inventors: Yunfu Luo, Chundao Yang, Maoyi Lei, Ling Liu, Guoping Hu, Jian Li, Shuhui Chen
  • 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR
    Publication number: 20200017528
    Abstract: The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee1, and includes an application of the compound in treating various types of tumors.
    Type: Application
    Filed: January 19, 2018
    Publication date: January 16, 2020
    Inventors: Wenyuan QIAN, Chundao YANG, Zhengwei LI, Jie LI, Jian LI, Shuhui CHEN
  • Cyclic compound acting as PDE4 inhibitor
    Patent number: 10532986
    Abstract: Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 14, 2020
    Assignee: Medshine Discovery Inc.
    Inventors: Yunfu Luo, Chundao Yang, Maoyi Lei, Lanbao Sun, Guoping Hu, Jian Li, Shuhui Chen
  • CYCLIC COMPOUND ACTING AS PDE4 INHIBITOR
    Publication number: 20190210975
    Abstract: Provided are a phosphodiesterase-4 (PDE4) inhibitor and application thereof in preparation of a medication for treating a disease related to PDE4. Specifically disclosed is a compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 22, 2017
    Publication date: July 11, 2019
    Inventors: Yunfu LUO, Chundao YANG, Maoyi LEI, Lanbao SUN, Guoping HU, Jian LI, Shuhui CHEN
  • PDE4 INHIBITOR
    Publication number: 20190177318
    Abstract: Provided are a PDE4 inhibitor and a use thereof in the preparation of a medicament for treating PDE4 related diseases. Specifically disclosed are the compound as shown in formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 13, 2019
    Inventors: Yunfu LUO, Chundao YANG, Maoyi LEI, LING LIU, Guoping HU, Jian LI, Shuhui CHEN
  • Btk inhibitors
    Patent number: 10214546
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: February 26, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang